Bank of America Begins Coverage on Akili (NASDAQ:AKLI)

Equities researchers at Bank of America started coverage on shares of Akili (NASDAQ:AKLIGet Rating) in a research note issued on Friday, Marketbeat Ratings reports. The brokerage set a “neutral” rating on the stock.

A number of other equities research analysts also recently commented on the stock. Credit Suisse Group raised their price objective on shares of Akili from $4.00 to $4.50 and gave the company an “outperform” rating in a report on Tuesday, November 15th. Cowen began coverage on Akili in a report on Tuesday, September 6th. They set an “outperform” rating for the company. Lifesci Capital reaffirmed an “outperform” rating on shares of Akili in a research report on Tuesday, September 6th. Finally, Cowen started coverage on Akili in a research note on Tuesday, September 6th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.50.

Akili Stock Performance

AKLI stock opened at $1.50 on Friday. The stock’s 50 day moving average price is $2.34. Akili has a fifty-two week low of $1.47 and a fifty-two week high of $37.58. The company has a debt-to-equity ratio of 0.11, a quick ratio of 12.27 and a current ratio of 12.27.

Institutional Trading of Akili

A number of large investors have recently made changes to their positions in the company. Temasek Holdings Private Ltd purchased a new stake in Akili in the third quarter valued at approximately $26,011,000. Neuberger Berman Group LLC acquired a new stake in Akili during the 3rd quarter worth $13,056,000. Baillie Gifford & Co. purchased a new position in Akili during the 3rd quarter worth $10,545,000. Comprehensive Financial Management LLC acquired a new position in Akili in the third quarter valued at $2,403,000. Finally, Revelation Capital Management LLC purchased a new stake in shares of Akili in the third quarter valued at about $556,000. 89.24% of the stock is owned by institutional investors and hedge funds.

About Akili

(Get Rating)

Akili, Inc, a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.

See Also

Analyst Recommendations for Akili (NASDAQ:AKLI)

Receive News & Ratings for Akili Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akili and related companies with MarketBeat.com's FREE daily email newsletter.